IAVI 004

Status:Completed

Phase:I

Principal Investigator(s):

Objective:Evaluate an MVA vector-based HIV-1 clade A candidate vaccine, MVA.HIVA, in HIV-uninfected, healthy Kenyan male and female volunteers at low risk for HIV infection

Prevention Option(s):HIV Vaccine

Study Design:Controlled, Double-blind, Placebo, Randomized

Arms and Assigned Interventions

DescriptionVolunteers will be screened up to 4 weeks before entry, will receive two doses of 5 x 10^7 pfu MVA.HIVA intradermally at 4 week intervals, and will be followed up for 189 days after the first immunization. Additional follow-up visits at 12 and 18 months after the first immunization will be scheduled.

Mode of DeliveryIntradermal

ARMsExperimental

Official Code: IAVI 004

Trial Sponsors: Kenya AIDS Vaccine Initiative-Kenyatta National Hospital (KAVI-KNH)

Start Date

End Date

none

Enrollment:18

Age range: ↔ any

Population:Cisgender Men, Cisgender Women

Stay up-to-date!